# OnCo record harmoni-2 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/harmoni-2/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "harmoni-2", "NCT05499390" ;
  schema:name "HARMONi-2"@en ;
  schema:description "The first head-to-head trial in which a new drug beat Keytruda, in China; a survival benefit followed in 2026."@en ;
  schema:url <https://onco.cc/trials/harmoni-2/> ;
  schema:dateModified "2026-09-06"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05499390>, <https://smmttx.com/news/press-releases/news-details/2026/Ivonescimab-Monotherapy-Demonstrates-Statistically-Significant-Overall-Survival-Benefit-Compared-to-Pembrolizumab-Monotherapy-in-PD-L1-Positive-Advanced-NSCLC-in-HARMONi-2-Study-Conducted-by-Akeso-in-China/default.aspx> ;
  onco:status "positive" ;
  onco:phase "3" ;
  schema:startDate "2022-11-09" ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/pdl1-high-nsclc/> ;
  onco:technologies <https://onco.cc/technologies/bispecific-antibody/>, <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:targets <https://onco.cc/targets/pd1/>, <https://onco.cc/targets/vegf/> ;
  onco:drugs <https://onco.cc/drugs/ivonescimab/>, <https://onco.cc/drugs/pembrolizumab/> ;
  onco:companies <https://onco.cc/companies/akeso/> ;
  onco:people <https://onco.cc/people/xia-michelle/>, <https://onco.cc/people/qing-zhou/>, <https://onco.cc/people/zhou-caicun/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-harmoni-2-lancet-2025/> .